

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10588627
Filing Date	2008-10-15
First Named Inventor	Laura EGGINK
Art Unit	1654
Examiner Name	Kosar, Andrew D
Attorney Docket Number	004908.00049

U.S.PATENTS						<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5677276		1997-10-14	Dickerson et al.	
	2	5753481		1998-05-19	Niwa et al.	
	3	5910310		1999-06-08	Heinen et al.	
	4	5919998		1999-07-06	Bandurski et al.	
	5	6159937		2000-12-12	Larsen et al.	
	6	6193981		2001-02-27	Goldstein	
	7	6498020		2002-12-24	Walker et al.	
	8	7105481		2006-09-12	Uutela et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10588627
	Filing Date	2008-10-15
	First Named Inventor	Laura EGGINK
	Art Unit	1654
	Examiner Name	Kosar, Andrew D
	Attorney Docket Number	004908.00049

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030073637		2003-04-17	Uutela et al.	
	2	20040031072		2004-02-12	La Rosa et al.	
	3	20040123343		2004-06-24	La Rosa et al.	
	4	20040248192		2004-12-09	Marchalonis et al.	
	5	20050063937		2005-03-24	Li et al.	
	6	20060024668		2006-02-02	Hock	
	7	20060078535		2006-04-13	Livant, Donna	
	8	20060148093		2006-07-06	Gygi et al.	
	9	20060160730		2006-07-20	Cuttitta et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number		10588627	
		Filing Date		2008-10-15	
		First Named Inventor		Laura EGGINK	
		Art Unit		1654	
		Examiner Name		Kosar, Andrew D	
		Attorney Docket Number		004908.00049	

10	20060189538	2006-08-24	Secombes et al.	
11	20060269519	2006-11-30	Chen et al.	
12	20060287234	2006-12-21	Breen et al.	
13	20070003542	2007-01-04	Zimmerman et al.	
14	20070021342	2007-01-25	Breen et al.	
15	20070149475	2007-06-28	Murray et al.	
16	20070154448	2007-07-05	Reid et al.	
17	20080102076	2008-05-01	Eggink et al.	
18	20090041793	2009-02-12	Eggink et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² 	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number		10588627	
		Filing Date		2008-10-15	
		First Named Inventor		Laura EGGINK	
		Art Unit		1654	
		Examiner Name		Kosar, Andrew D	
		Attorney Docket Number		004908.00049	

	1	03/091275	WO		2003-11-06	Savarino, Andrea		<input type="checkbox"/>
	2	04/011650	WO		2004-02-05	Intercell AG		<input type="checkbox"/>
	3	05/087793	WO		2005-09-22	Arizona Board of Regents		<input type="checkbox"/>
	4	06/063028	WO		2006-06-15	Arizona Board of Regents		<input type="checkbox"/>
	5	2006/105021	WO		2006-10-05	Tolerrx, Inc.		<input type="checkbox"/>
	6	2290722	CA		2001-06-08	Novopharm Biotech		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	CHARGELEGUE et al., "A Peptide Mimic of a Protective Epitope of Respiratory Syncytial Virus Selected from a Combinatorial Library Induces Virus-Neutralizing Antibodies and Reduces Viral Load in Vivo", Journal of Virology, 72 (3):2040-2046 (March 1998).	<input type="checkbox"/>
	2	CHERSI et al., "Specifications of rabbit antisera to multiple antigen (MAP) peptides", Journal of Biosciences, 50 (9-10):735-738 (September 1, 1995) ABSTRACT ONLY.	<input type="checkbox"/>
	3	CIESIELSKI et al., "Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model", Cancer Immunol Immunother, 54:107-119 (2005).	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number	10588627
		Filing Date	2008-10-15
		First Named Inventor	Laura EGGINK
		Art Unit	1654
		Examiner Name	Kosar, Andrew D
		Attorney Docket Number	004908.00049

	4	EGGINK et al., "A biologically active peptide mimetic of N-acetylgalactosamine/galactose", BMC Research Notes, 2:23 (2009).	<input type="checkbox"/>
	5	G.FÄTKENHEUER et al., "Efficacy of Short-Term Monotherapy with Maraviroc, a New CRC5 Antagonist, in Patients Infected with HIV 1," Nature Med (2005), Vol. 11, pp. 1170-1172.	<input type="checkbox"/>
	6	J. COHEN, "Hope on New AIDS Drugs, but Breast-Feeding Strategy Backfires," Science (2007), Vol. 315, pp. 1357.	<input type="checkbox"/>
	7	J. STOVER et al., "The Global Impact of Scaling up HIV/AIDS Prevention Programs in Low-and Middle-Income Countries," Science (2006) Vol. 311, pp. 1474-1476.	<input type="checkbox"/>
	8	MANKI et al., "Vaccination with Multiple Antigen Peptide as Rejection Antigen Peptide in Murine Leukemia", Cancer Research, 58:1960-1964 (May 1, 1998).	<input type="checkbox"/>
	9	NICOLAUS, "Symbiotic Approach to Drug Design", Decision Making in Drug Research, pp. 173-186 (January 1, 1983).	<input type="checkbox"/>
	10	OLSZEWSKA et al., "Protection against Measles Virus-Induced Encephalitis by Anti-mimotope Antibodies: The Rose of Antibody Affinity" Virology, 272(1):98-105 (June 20, 2000).	<input type="checkbox"/>
	11	P.W. LATHAM, "Therapeutic Peptides Revisited," Nature Biotech (1999), vol. 17, pp. 755-757.	<input type="checkbox"/>
	12	SARIG et al., "Telomeric and Tetraplex DNA Binding Properties of qTBP42: A Homologue of the CArG Box Binding Protein CBF-A", Biochemical and Biophysical Research Communications 1997, Volume 237, Number 3, pages 617-623	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10588627
	Filing Date	2008-10-15
	First Named Inventor	Laura EGGINK
	Art Unit	1654
	Examiner Name	Kosar, Andrew D
	Attorney Docket Number	004908.00049

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.